Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 14/20 | 0.69 |
| ▸ | INSR | P06213 | 6/20 | 0.60 |
| ▸ | IGF1R | P08069 | 6/20 | 0.60 |
| ▸ | ALK | Q9UM73 | 6/20 | 0.60 |
| ▸ | MET | P08581 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26907018 | 0.95 | EGFR (0.67) | EGFRINSRIGF1RALKMET | |
| SCHEMBL29114859 | 0.91 | EGFR (0.62) | EGFRINSRIGF1RALK | |
| SCHEMBL26906804 | 0.91 | EGFR (0.73) | EGFRINSRIGF1RALKMET | |
| SCHEMBL26906822 | 0.90 | EGFR (0.72) | EGFRINSRIGF1RALKMET | |
| SCHEMBL26906637 | 0.90 | EGFR (0.82) | EGFRINSRIGF1RALKMET | |
| SCHEMBL26906764 | 0.89 | EGFR (0.70) | EGFRINSRIGF1RALKMET | |
| SCHEMBL26906638 | 0.88 | EGFR (0.69) | EGFRINSRIGF1RALKMET | |
| SCHEMBL30692638 | 0.88 | EGFR (0.69) | EGFRINSRIGF1RALKMET | |
| SCHEMBL26906683 | 0.88 | EGFR (0.67) | EGFRINSRIGF1RALKMET | |
| SCHEMBL26906840 | 0.88 | EGFR (0.69) | EGFRINSRIGF1RALKMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228458-A1 | PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME | THERAPEX CO., LTD. (KR) | 2024-07-11 | — | — | US | claimed |
| EP-4286376-A1 | PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME | Therapex Co., Ltd. (KR) | 2023-12-06 | — | — | EP | claimed |
| US-20240228458-A1 | PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME | THERAPEX CO., LTD. (KR) | 2024-07-11 | — | — | US | disclosed |
| EP-4286376-A1 | PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME | Therapex Co., Ltd. (KR) | 2023-12-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228458-A1 | PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME | EGFR, ERBB2, ERBB3 | EGFR 1/4885INSR 607/4885IGF1R 592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.